![First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - ScienceDirect First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500219303939-gr4.jpg)
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - ScienceDirect
![Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer - Journal of Thoracic Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer - Journal of Thoracic](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040441917/2053936481/gr1.jpg)
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer - Journal of Thoracic
![Summary box of LUX-Lung trials with afatinib in non-small cell lung... | Download Scientific Diagram Summary box of LUX-Lung trials with afatinib in non-small cell lung... | Download Scientific Diagram](https://www.researchgate.net/publication/296484081/figure/fig1/AS:566079900196864@1511975373121/Summary-box-of-LUX-Lung-trials-with-afatinib-in-non-small-cell-lung-cancers.png)
Summary box of LUX-Lung trials with afatinib in non-small cell lung... | Download Scientific Diagram
![Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - Annals of Oncology Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/493df784-3f19-49b9-a414-3bf71ea109ad/gr1.jpg)
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - Annals of Oncology
![Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations - Clinical Lung Cancer Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations - Clinical Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/af043b17-9090-4d6c-bbc8-0612229ae770/gr1.jpg)
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations - Clinical Lung Cancer
![Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 - The Lancet Oncology Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a331ef2a-dfa6-44c9-b5fa-48afbddcd937/gr3_lrg.jpg)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 - The Lancet Oncology
![LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download](https://slideplayer.com/11581947/42/images/slide_1.jpg)
LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download
![First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - Lung Cancer First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - Lung Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f412ec1f-cfa5-442f-9565-ad6dcc57e85d/gr1_lrg.jpg)
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - Lung Cancer
![Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5ef8ddbd-9b94-4d5e-bdf8-0995af22c16b/gr1.gif)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology
![Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer - Cancer Treatment Reviews Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cf09a5c0-284d-4c7b-b7f1-0cecd4a71c87/gr1_lrg.jpg)
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer - Cancer Treatment Reviews
![Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial - The Lancet Oncology Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2788dc04-e45a-4fce-9233-274740cfad7a/gr1_lrg.gif)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial - The Lancet Oncology
![Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study - Lung Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study - Lung](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2099023071/2078923772/gr1.jpg)
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study - Lung
![EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options - memoinOncology EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options - memoinOncology](https://memoinoncology.com/wp-content/uploads/2020/02/78061.jpg)
EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options - memoinOncology
![LUX Lung 3 Clinical Trial Infographic (Boehringer Ingelheim) | Clinical trials, Boehringer ingelheim, Trials LUX Lung 3 Clinical Trial Infographic (Boehringer Ingelheim) | Clinical trials, Boehringer ingelheim, Trials](https://i.pinimg.com/736x/11/c3/3c/11c33c4905025851202c33a292f94ad0--boehringer-ingelheim-lungs.jpg)
LUX Lung 3 Clinical Trial Infographic (Boehringer Ingelheim) | Clinical trials, Boehringer ingelheim, Trials
![PFS in recent head-to-head trials: (a) Lux-Lung 7, (b) ARCHER 1050 and... | Download Scientific Diagram PFS in recent head-to-head trials: (a) Lux-Lung 7, (b) ARCHER 1050 and... | Download Scientific Diagram](https://www.researchgate.net/publication/322649349/figure/fig1/AS:585784834940928@1516673396384/PFS-in-recent-head-to-head-trials-a-Lux-Lung-7-b-ARCHER-1050-and-c-FLAURA-a.png)
PFS in recent head-to-head trials: (a) Lux-Lung 7, (b) ARCHER 1050 and... | Download Scientific Diagram
![Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3 | Future Oncology Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3 | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2019-0659/asset/images/medium/figure4.gif)
Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3 | Future Oncology
![LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download](https://images.slideplayer.com/42/11581947/slides/slide_4.jpg)